Modern Drug Discovery Home Page

Table of Contents

July/August 1999
Volume 2, Number 4

FEATURES

	Combinatorial biosynthesis: Panning for pharmaceutical gold John K. Borchardt Genetic engineering may keep one of the richest drug gold mines from being played out.
	The mysterious placebo effect Carol Hart Understanding it can help avoid flawed study designs.
	The liposome maker's art: Wrapping toxic drugs in lipid disguises Jim Kling Researchers turn amphoterrible into Amphotec and doxorubicin into Doxil.
	Through the looking glass in chiral drug development John Caldwell Focusing on one stereoisomer may increase efficacy, reduce side effects, or even extend patent protection.
	Content and discontent: A combinatorial chemistry status report Richard K. Brown The new technology has put drug candidates into clinical trials, but it still hasn't won full acceptance by medicinal chemists.
	High-throughput characterization of combinatorial libraries James N. Kyranos and Joseph C. Hogan, Jr. Generating and interpreting a large amount of analytical data are necessary to take advantage of combichem's achievements.

DEPARTMENTS

	Editorial
	In Brief Discovery may lead to osteoporosis drugs Selectins for inflammation therapy and drug delivery The new kid on the anti-obesity block More cancer drug trials needed A new class of HIV drugs New option for ADHD treatment An atherosclerosis-Chlamydia pneumoniae connection? Fish malodor syndrome Genetic connection for SAD Mapping the stroke damaged brain Alzheimer's and schizophrenia
	Analysis Selecting leads with pharmacokinetic data
	Financial Matters
	Health Topics
	Web Scan
	Reviews Gout: The Patrician Malady Chiral Chromatography Combinatorial Chemistry and Molecular Diversity in Drug Discovery
	New Products
	Meetings
	Ad Index
	Et Cetera Women and cardiovascular disease